{"id":"shr-a1811","safety":{"commonSideEffects":[{"rate":null,"effect":"unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR-A1811 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"SHR-A1811 is a small molecule targeting the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:08.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07489703","phase":"PHASE2","title":"SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-30","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT06649331","phase":"PHASE2","title":"Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-21","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)","enrollment":160},{"nctId":"NCT07203729","phase":"PHASE2","title":"The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis","enrollment":184},{"nctId":"NCT07466303","phase":"PHASE2","title":"Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2026-03-25","conditions":"Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer","enrollment":84},{"nctId":"NCT07466927","phase":"PHASE2","title":"Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-15","conditions":"HER2-negative Breast Cancer","enrollment":30},{"nctId":"NCT06057610","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-10-16","conditions":"HER2-PositiveRecurrent or Metastatic Breast Cancer","enrollment":868},{"nctId":"NCT07417241","phase":"PHASE2","title":"SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03-31","conditions":"Breast Cancer, HER2-positive Breast Cancer","enrollment":100},{"nctId":"NCT05671822","phase":"PHASE2","title":"Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-03-14","conditions":"HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma","enrollment":258},{"nctId":"NCT07118527","phase":"PHASE3","title":"A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-18","conditions":"Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":600},{"nctId":"NCT07393425","phase":"PHASE2","title":"Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-02","conditions":"HER2 + Breast Cancer","enrollment":50},{"nctId":"NCT04513223","phase":"PHASE1","title":"A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-30","conditions":"Gastric Cancer, Colorectal Cancer","enrollment":101},{"nctId":"NCT07382687","phase":"PHASE3","title":"Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-26","conditions":"Breast Cancer","enrollment":248},{"nctId":"NCT07377916","phase":"NA","title":"Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2026-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07196774","phase":"PHASE3","title":"A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-23","conditions":"Early-stage or Locally Advanced HER2-positive Breast Cancer","enrollment":740},{"nctId":"NCT06430437","phase":"PHASE3","title":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-29","conditions":"Non-Small Cell Lung Cancer With HER2- Mutations","enrollment":300},{"nctId":"NCT07340398","phase":"PHASE2","title":"Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-12-25","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT07355764","phase":"PHASE2","title":"MA-CRC-II-016 SHR-1811","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-30","conditions":"mCRC, HER2, Targeted Therapy","enrollment":80},{"nctId":"NCT07275242","phase":"PHASE1","title":"A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-12-23","conditions":"Solid Tumor","enrollment":107},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT06547736","phase":"PHASE2","title":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-14","conditions":"Pancreatic Cancer","enrollment":160},{"nctId":"NCT07317778","phase":"PHASE2","title":"Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-15","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer","enrollment":249},{"nctId":"NCT07037199","phase":"PHASE2","title":"Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-18","conditions":"Advanced Breast Cancer","enrollment":45},{"nctId":"NCT07309770","phase":"PHASE2","title":"Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies","status":"RECRUITING","sponsor":"Sheng Zhang","startDate":"2025-12-18","conditions":"Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates","enrollment":90},{"nctId":"NCT07307287","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-20","conditions":"SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer","enrollment":30},{"nctId":"NCT07305246","phase":"PHASE2","title":"Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2025-12","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT07241793","phase":"PHASE2","title":"Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-20","conditions":"Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent","enrollment":96},{"nctId":"NCT07111832","phase":"PHASE3","title":"A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-20","conditions":"PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer","enrollment":400},{"nctId":"NCT07281209","phase":"PHASE2","title":"A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-12","conditions":"NSCLC","enrollment":40},{"nctId":"NCT07232849","phase":"PHASE2","title":"A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-04","conditions":"Lung Cancer","enrollment":100},{"nctId":"NCT05076682","phase":"PHASE2","title":"Reverse Triple Negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-30","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT05924256","phase":"PHASE2","title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Advanced Salivary Gland Carcinoma","enrollment":88},{"nctId":"NCT07051486","phase":"PHASE2","title":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-10-11","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":60},{"nctId":"NCT06840002","phase":"PHASE1, PHASE2","title":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-03-18","conditions":"Ovarian Cancer","enrollment":150},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT07177950","phase":"PHASE1, PHASE2","title":"A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-09-30","conditions":"Breast Cancer, Brain Metastases, Leptomeningeal Metastasis","enrollment":51},{"nctId":"NCT04446260","phase":"PHASE1","title":"A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-09-07","conditions":"Advanced Solid Tumors","enrollment":396},{"nctId":"NCT07102901","phase":"PHASE2","title":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-09-05","conditions":"Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT07129187","phase":"PHASE2","title":"SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response","status":"NOT_YET_RECRUITING","sponsor":"Chuan Wang","startDate":"2025-10","conditions":"Early Breast Cancer, HER2 + Breast Cancer, Stage II Breast Cancer","enrollment":30},{"nctId":"NCT05424835","phase":"PHASE3","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-08-04","conditions":"HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","enrollment":381},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07132242","phase":"PHASE2","title":"SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-30","conditions":"Metastatic Breast Cancer With HER2 Positive","enrollment":84},{"nctId":"NCT06973525","phase":"PHASE2","title":"This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-09-01","conditions":"HER2-positive Breast Cancer","enrollment":30},{"nctId":"NCT06199973","phase":"PHASE3","title":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-03-01","conditions":"Advanced Colorectal Cancer","enrollment":130},{"nctId":"NCT07047443","phase":"PHASE2","title":"SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-08-01","conditions":"Breast Cancer","enrollment":18},{"nctId":"NCT06927180","phase":"PHASE2","title":"SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-04-16","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":180},{"nctId":"NCT06859775","phase":"PHASE1, PHASE2","title":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-04-25","conditions":"Recurrent or Metastatic Cervical Cancer","enrollment":100},{"nctId":"NCT06990516","phase":"PHASE1, PHASE2","title":"SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":90},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06975462","phase":"PHASE2","title":"A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Breast Cancer Metastatic","enrollment":30},{"nctId":"NCT06975475","phase":"PHASE2","title":"SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-01","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT06126640","phase":"PHASE3","title":"A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-11-20","conditions":"HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy","enrollment":1600},{"nctId":"NCT06710990","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-02-17","conditions":"Advanced Breast Cancer","enrollment":32},{"nctId":"NCT06788197","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2025-03","conditions":"Breast Cancer, Locally Advanced or Metastatic Breast Cancer","enrollment":52},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":"Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","enrollment":140},{"nctId":"NCT06778031","phase":"PHASE2","title":"A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-02-26","conditions":"HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer","enrollment":54},{"nctId":"NCT06718933","phase":"PHASE1, PHASE2","title":"Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-08","conditions":"Breast Cancer Metastatic, Breast Cancer Brain Metastases","enrollment":74},{"nctId":"NCT06340230","phase":"PHASE2","title":"SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2024-08-23","conditions":"HR Positive/HER2 Low Breast Cancer","enrollment":93},{"nctId":"NCT06222879","phase":"PHASE1, PHASE2","title":"Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2024-02-20","conditions":"Breast Cancer","enrollment":350},{"nctId":"NCT05911958","phase":"PHASE2","title":"A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-07-05","conditions":"HER2 Low Breast Carcinoma","enrollment":66},{"nctId":"NCT06666166","phase":"PHASE2","title":"SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-12","conditions":"Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer","enrollment":28},{"nctId":"NCT05769010","phase":"PHASE2","title":"Study of SHR-A1811 in HER2-expression Advanced Breast Cancer with Brain Metastases","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2023-03-31","conditions":"Metastatic Breast Cancer","enrollment":125},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT06592625","phase":"PHASE2","title":"Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-09-20","conditions":"Untreated Early-stage or Locally Advanced Breast Cancer","enrollment":60},{"nctId":"NCT06015048","phase":"PHASE1, PHASE2","title":"A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-08-11","conditions":"HER2-expressing Advanced Solid Tumors","enrollment":364},{"nctId":"NCT06413745","phase":"PHASE2","title":"Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-06-04","conditions":"HER2 Expression / Amplification in Patients With Biliary Tract Cancer","enrollment":65},{"nctId":"NCT05635487","phase":"PHASE2","title":"A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2023-03-16","conditions":"HER2-positive Breast Cancer","enrollment":65},{"nctId":"NCT04818333","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-04-23","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":157},{"nctId":"NCT06433609","phase":"PHASE2","title":"Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-06","conditions":"Advanced Breast Cancer","enrollment":131},{"nctId":"NCT06411457","phase":"PHASE2","title":"SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-16","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT06361979","phase":"PHASE2","title":"SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases","status":"NOT_YET_RECRUITING","sponsor":"Huihua Xiong","startDate":"2024-05","conditions":"Breasr Cancer","enrollment":30},{"nctId":"NCT06123494","phase":"PHASE3","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-01-09","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":360},{"nctId":"NCT05749588","phase":"PHASE2","title":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-03-30","conditions":"Triple-negative Breast Cancer","enrollment":120},{"nctId":"NCT05482568","phase":"PHASE1, PHASE2","title":"A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-09-15","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":324},{"nctId":"NCT05353361","phase":"PHASE2","title":"A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-23","conditions":"Breast Cancer","enrollment":402},{"nctId":"NCT05896020","phase":"PHASE2","title":"A Study of SHR-A1811 in Subjects With Gynaecologic Oncology","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-10","conditions":"Gynaecological Malignancies","enrollment":225},{"nctId":"NCT05845138","phase":"PHASE1, PHASE2","title":"A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2023-07-25","conditions":"Breast Cancer","enrollment":116},{"nctId":"NCT05814354","phase":"PHASE3","title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-06-30","conditions":"Breast Cancer","enrollment":530},{"nctId":"NCT05824325","phase":"PHASE1, PHASE2","title":"Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-03-14","conditions":"Breast Cancer","enrollment":56},{"nctId":"NCT05792410","phase":"PHASE1, PHASE2","title":"A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-04","conditions":"HER2 Low Advanced or Metastatic Breast Cancer","enrollment":300},{"nctId":"NCT05349409","phase":"PHASE2","title":"A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-06-09","conditions":"Advanced Solid Tumors","enrollment":212}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trastuzumab-rezetecan","Trastuzumab Rezetecan","T-DXh"],"phase":"phase_3","status":"active","brandName":"SHR-A1811","genericName":"SHR-A1811","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A1811 is a small molecule targeting the molecular target. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}